Cite
Overview of the European Medicines Agency's Development of Product‐Specific Bioequivalence Guidelines.
MLA
on behalf of the Pharmacokinetics Working Party, et al. “Overview of the European Medicines Agency’s Development of Product‐Specific Bioequivalence Guidelines.” Clinical Pharmacology & Therapeutics, vol. 104, no. 3, Sept. 2018, pp. 539–45. EBSCOhost, https://doi.org/10.1002/cpt.957.
APA
on behalf of the Pharmacokinetics Working Party, Sullivan, J. O., Blake, K., Berntgen, M., Salmonson, T., & Welink, J. (2018). Overview of the European Medicines Agency’s Development of Product‐Specific Bioequivalence Guidelines. Clinical Pharmacology & Therapeutics, 104(3), 539–545. https://doi.org/10.1002/cpt.957
Chicago
on behalf of the Pharmacokinetics Working Party, Jane O’ Sullivan, Kevin Blake, Michael Berntgen, Tomas Salmonson, and Jan Welink. 2018. “Overview of the European Medicines Agency’s Development of Product‐Specific Bioequivalence Guidelines.” Clinical Pharmacology & Therapeutics 104 (3): 539–45. doi:10.1002/cpt.957.